These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 10917205

  • 1. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J, Chen Y, Moyana T.
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [Abstract] [Full Text] [Related]

  • 2. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
    Wright P, Zheng C, Moyana T, Xiang J.
    Cancer Gene Ther; 1998 Jul; 5(6):371-9. PubMed ID: 9917092
    [Abstract] [Full Text] [Related]

  • 3. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J.
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [Abstract] [Full Text] [Related]

  • 4. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 5. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D, Moyana T, Xiang J.
    Cell Res; 2006 Mar 01; 16(3):241-59. PubMed ID: 16541123
    [Abstract] [Full Text] [Related]

  • 6. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
    Xiang J, Qi Y, Chen Y.
    Cancer Gene Ther; 1997 Jan 01; 4(6):353-8. PubMed ID: 9408605
    [Abstract] [Full Text] [Related]

  • 9. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z, Shi M, Chan T, Sas S, Xu S, Xiang J.
    Cancer Gene Ther; 2007 Jul 01; 14(7):661-75. PubMed ID: 17479109
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS, Chung SW, Kim SH, Kang BY, Hwang SY, Lee JW.
    Cancer Gene Ther; 2000 Jun 01; 7(6):861-9. PubMed ID: 10880016
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
    Zhang W, Yang H, Wang Z, Jim X.
    Chin Med J (Engl); 2002 Dec 01; 115(12):1767-71. PubMed ID: 12622920
    [Abstract] [Full Text] [Related]

  • 17. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
    Campbell I, Moyana T, Carlsen S, Zheng C, Xiang J.
    Cancer Gene Ther; 2000 Jan 01; 7(1):37-44. PubMed ID: 10678354
    [Abstract] [Full Text] [Related]

  • 18. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
    Huang H, Bi XG, Yuan JY, Xu SL, Guo XL, Xiang J.
    Gene Ther; 2005 Jun 01; 12(12):999-1010. PubMed ID: 15789061
    [Abstract] [Full Text] [Related]

  • 19. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1996 Aug 01; 26(8):1851-9. PubMed ID: 8765031
    [Abstract] [Full Text] [Related]

  • 20. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T, Miyazawa N, Moore MA, Crystal RG.
    Cancer Res; 2000 Nov 15; 60(22):6391-5. PubMed ID: 11103803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.